COVID-19
Excerpt from the Press Release: INDIANAPOLIS, April 8, 2021 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily plus standard of care (SoC) versus placebo plus SoC. The trial did not meet statistical significance on the primary endpoint, which…
Read More
Excerpt from the Press Release: PHILADELPHIA — David C. Fajgenbaum, MD, MBA, MSc, an assistant professor of Translational Medicine & Human Genetics and director of the Center for Cytokine Storm Treatment & Laboratory at the Perelman School of Medicine at the University of Pennsylvania, was awarded $1 million by the Parker Institute for Cancer Immunotherapy…
Read More
Excerpt from the Press Release: WARMINSTER, Pa. and WALTHAM, Mass. and MUNICH, Germany, April 01, 2021 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (NASDAQ: ABUS), X-Chem, Inc. (X-Chem) and Proteros biostructures GmbH (Proteros) announced today that they have entered into a discovery research and license agreement focused on the discovery of novel inhibitors targeting the SARS-CoV-2…
Read More
Excerpt from the Press Release: The preclinical study found CureVac’s candidate, dubbed CVnCoV, protected mice against COVID-19 in a virus challenge study with the B.1.351 variant of the SARS-CoV-2 virus. The variant, first identified in South Africa, bears certain mutations that make it more contagious than the original virus. It marks the first mouse challenge…
Read More
Excerpt from the Article: Meissa Vaccines’ intranasal live attenuated chimeric virus-based vaccine for SARS-CoV-2 (and its variants) recently was cleared for Phase I trials, which will start at the end of March. Unlike other live attenuated virus vaccines, it employs codon deoptimization to evoke a stronger-than-usual immune response. If approved, it holds the potential of…
Read More
Excerpt from the Press Release: SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today updated positive results from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC™) for patients suffering from COVID-19-induced acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS). This ongoing study (MSC-COV-101) is a single arm, non-randomized Phase 1b study of the safety and preliminary efficacy of COVI-MSCs administered every other day for…
Read More Excerpt from the Press Release: WILMINGTON, Del.–(BUSINESS WIRE)–The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalization. This interim safety and efficacy analysis was based on 32,449 participants accruing 141 symptomatic cases of COVID-19. The trial had…
Read More
Excerpt from the Article: A radiology workflow artificial intelligence (AI) solution from RADLogics can help providers truncate their turn-around time for COVID-19 detection cases by up to 30 percent, according to a recently released study. According to a clinical trial conducted at the Moscow Center for Diagnostics & Telemedicine, employing this AI solution to evaluate…
Read More
Excerpt from the Article: Ultrasound could be a disruptive tool in the fight against COVID-19, according to new research. A recent study published in the Journal of the Mechanics and Physics of Solids has found that the structure of the coronavirus may be vulnerable to the vibrations of an ultrasound with frequencies commonly used in…
Read More Excerpt from the Press Release: SAN DIEGO, March 11, 2021 /PRNewswire/ — Persephone Biosciences Inc., a privately held, data-driven microbiome-focused biotechnology company, today announced the initiation of the VOICES clinical study to determine the impact of gut microbiome composition and function on the immune system and efficacy of COVID-19 vaccination. VOICES (Vaccine Observation to Include all…
Read More